Targets › PGF
4 programs from 4 companies in 13 trials: 4 Phase 4, 4 Phase 3, 4 Phase 2, 1 Phase 1; Ophthalmology, Metabolic and endocrine, Oncology; next expected readout Jan 2027.
Growth factor active in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. (UniProt, P49763)
Open in Phaseline: the race on PGF, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai Eye Disease Prevention and Treatment Center | Conbercept Vascular endothelial growth factor A inhibitor; Vascular endothelial growth factor B inhibitor; Placenta growth factor inhibitor | VEGFA, VEGFB, PGF, VEGFC | Phase 4 | Diabetic Macular Edema | – |
| Regeneron Pharmaceuticals | Aflibercept Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor | VEGFA, PGF | Phase 3 | Neovascular Age-Related Macular Degeneration; Diabetic Maculopathy; Diabetic Macular Edema (DME); Proliferative Diabetic Retinopathy (PDR) … | Jan 2027 |
| Ashvattha Therapeutics | Aflibercept (D-4517) Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor | VEGFA, PGF | Phase 2 | Neovascular Age-related Macular Degeneration | – |
| Samsung Bioepis | Aflibercept (SB15) Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor | VEGFA, PGF | Phase 2 | Neovascular Age-related Macular Degeneration | – |
Neovascular Age-related Macular Degeneration (3) Diabetic Macular Edema (1) Neovascular Age-Related Macular Degeneration (1) Diabetic Maculopathy (1) Diabetic Macular Edema (DME) (1) Proliferative Diabetic Retinopathy (PDR) (1) Polypoidal Choroidal Vasculopathy (1) Severe Diabetic Macular Oedema (1) Eye Diseases (1) Metastatic Uveal Melanoma (1) Clinical Stage IV Cutaneous Melanoma AJCC v8 (1)
antibody (4)
Shanghai Eye Disease Prevention and Treatment Center (1) Regeneron Pharmaceuticals (1) Ashvattha Therapeutics (1) Samsung Bioepis (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.